Eli Lilly and and Amylin Pharmaceuticals has announced that exenatide is very effective in controlling blood sugar levels, at par with iphasic insulin aspart 30/70 (NovoMix by NovoNordisk). This finding was revealed after a threadbare study conducted by the company. This is indeed a boon to people suffering type 2 diabetes and unable to control the blood sugar with the oral diabetes drugs.
The study, which spanned a year, revealed that thirty-two percent of study participants using exenatide were able to effectively attain the target HbA1C of 7 percent or less. HbA1C is a measure of individuals average glucose level, a gauge commonly used by the specialists. The study also revealed that many patients using exenatide also experienced weight loss, an average of 2.5 kilograms (5.5 pounds), while the patients receiving biphasic insulin aspart had actually gained an average of 2.9 kilograms (6.4 pounds).
"This comparator study demonstrates that exenatide has similar blood glucose control to the conventional treatment with insulin," said Professor Dr. Michael Nauck, Director of the Diabetes Centre in Bad Lauterberg, Germany, and a lead author of the study.
Exenatide happens to be the first among a relatively new class of medicines known as incretin mimetics, which is approved, by the U.S. Food and Drug Administration for the treatment of type 2 diabetes.